You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

 

Online download statistics by month:

Online download statistics by month: July 2020 to March 2024

AbstractFullPdf
Jul 2020681683362
Aug 2020268269110
Sep 202016316366
Oct 202016916958
Nov 202010210141
Dec 2020999932
Jan 202118018060
Feb 202112412458
Mar 202112912960
Apr 202112612633
May 202112312350
Jun 202110610537
Jul 202111511534
Aug 202130430439
Sep 202110210242
Oct 202112012165
Nov 202110410470
Dec 2021808326
Jan 202212313530
Feb 2022788331
Mar 202214314854
Apr 202212814451
May 202212112756
Jun 202210310954
Jul 202210110772
Aug 2022858724
Sep 202210311043
Oct 202213418449
Nov 202211111150
Dec 2022686935
Jan 2023777835
Feb 2023949828
Mar 2023939461
Apr 2023606027
May 2023565617
Jun 202350509
Jul 2023555522
Aug 2023676914
Sep 2023919130
Oct 202310410418
Nov 202325926029
Dec 202354654633
Jan 202441942031
Feb 2024898941
Mar 2024798052
Total653266642239